Nautilus Partners with Baylor College for Early Access Program
Nautilus Biotechnology announced Baylor College of Medicine as the first customer of Nautilus' Iterative Mapping Early Access Program. Through a National Institutes of Health, or NIH, U01-funded study, Baylor will leverage Nautilus' novel single-molecule proteomics method to address a central challenge in cancer research - identifying aberrant protein isoforms that contribute to tumor growth, metastasis, immune evasion, and therapeutic resistance - while Nautilus expands early commercial access to its validated tau proteoforms assay. The study aims to develop a broadly accessible computational toolkit with improved detection of protein isoforms in conventional shotgun proteomics datasets. By pairing these computational approaches with full-length, isoform-resolved proteomic measurements generated on the Nautilus Voyager Platform, the project is intended to enable direct comparison of transcriptional and proteomic changes at unprecedented resolution.
Trade with 70% Backtested Accuracy
Analyst Views on NAUT
About NAUT
About the author
Nautilus Biotechnology Q4 2025 Earnings Call Highlights
- Successful Product Launch: Nautilus unveiled the Voyager instrument at the US Human Proteome Organization Conference, receiving positive feedback that indicates strong interest from researchers in new protein measurement technologies, suggesting a growing market demand.
- Early Access Program Initiation: The company launched the Early Access Program for Iterative Mapping ahead of schedule, marking a transition from development to active customer engagement, which is expected to enhance customer relationships and drive future revenue growth.
- Improved Financial Performance: Total operating expenses for Q4 2025 were $15.4 million, a 23% decrease year-over-year, with cash burn at $50.2 million, down from 2024, demonstrating effective cost control and resource allocation.
- Optimistic Future Outlook: The company anticipates a 15%-20% increase in total operating expenses for 2026, with plans for primary revenue growth to begin in 2027, reflecting Nautilus's confidence in its commercialization strategy and market positioning.
Nautilus Biotechnology Reports Q4 Earnings and 2026 Outlook
- Earnings Performance: Nautilus Biotechnology reported a Q4 GAAP EPS of -$0.11, beating expectations by $0.03, indicating initial success in cost control despite remaining in the red.
- Cash Position: As of December 31, 2025, the company had $156.1 million in cash, cash equivalents, and investments, reflecting a degree of financial stability that can support future operational needs in the current economic climate.
- 2026 Outlook: The company anticipates no material revenue from its Early Access Program engagements in 2026, while expecting operating expenses to rise by 15-20% year-over-year, which may pressure profitability.
- Sufficient Funding: Based on its cash reserves as of December 31, 2025, Nautilus Biotechnology believes it has adequate resources to fund operations through 2027, demonstrating confidence and foresight in its financial management.
BETA Technologies Upgraded to Buy by Jefferies Amid Potential Catalysts
- Jefferies Upgrade: On February 11, 2026, Jefferies analyst Sheila Kahyaoglu upgraded BETA Technologies from Hold to Buy with a $30 price target, indicating that the shares are compelling at current levels following recent risk-off trading, suggesting potential for future gains.
- Amazon Investment Increase: As of December 31, 2025, Amazon acquired a $331.58 million position in BETA Technologies, making it one of its largest equity holdings, reflecting confidence in the electric aviation market and potentially providing financial support for BETA's future developments.
- Partnership Initiative: Surf Air Mobility announced a collaboration with the Hawaii Department of Transportation and BETA Technologies for the Electric Vertical Takeoff and Landing Integration Pilot Program, aiming to integrate airline operations with electric aircraft technology, which could enhance infrastructure development in Hawaii if selected.
- Electric Aviation Market Potential: BETA Technologies focuses on developing electric aircraft and propulsion systems, and as demand for sustainable aviation solutions grows, the company's technological innovations in the electric aviation sector are expected to drive significant future growth.
Nautilus (NAUT) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth
Biotech Stocks Momentum: Several small-cap biotech stocks, including Nautilus Biotechnology and PepGen, are experiencing renewed investor interest due to insider buying, strategic partnerships, and clinical trial advancements, leading to notable after-hours gains.
Nautilus Biotechnology Highlights: Nautilus saw a significant rise in stock price following insider purchases by its CEO and a partnership with the Allen Institute, alongside a reported narrower loss and strong cash position.
Lixte Biotechnology's Financial Strategy: Lixte announced a $2.6 million investment in Bitcoin and Ethereum to diversify its treasury, reflecting a strategic shift aimed at enhancing flexibility in the digital economy.
RenovoRx and VolitionRx Developments: RenovoRx received positive feedback for its pancreatic cancer trial and is expanding commercialization efforts, while VolitionRx entered a partnership to advance its diagnostic technology for Antiphospholipid Syndrome.
Nautilus Biotechnology Q4 2025 Earnings Call Highlights
- Successful Product Launch: Nautilus unveiled the Voyager instrument at the US Human Proteome Organization Conference, receiving positive feedback that indicates strong interest from researchers in new protein measurement technologies, suggesting a growing market demand.
- Early Access Program Initiation: The company launched the Early Access Program for Iterative Mapping ahead of schedule, marking a transition from development to active customer engagement, which is expected to enhance customer relationships and drive future revenue growth.
- Improved Financial Performance: Total operating expenses for Q4 2025 were $15.4 million, a 23% decrease year-over-year, with cash burn at $50.2 million, down from 2024, demonstrating effective cost control and resource allocation.
- Optimistic Future Outlook: The company anticipates a 15%-20% increase in total operating expenses for 2026, with plans for primary revenue growth to begin in 2027, reflecting Nautilus's confidence in its commercialization strategy and market positioning.
Nautilus Biotechnology Reports Q4 Earnings and 2026 Outlook
- Earnings Performance: Nautilus Biotechnology reported a Q4 GAAP EPS of -$0.11, beating expectations by $0.03, indicating initial success in cost control despite remaining in the red.
- Cash Position: As of December 31, 2025, the company had $156.1 million in cash, cash equivalents, and investments, reflecting a degree of financial stability that can support future operational needs in the current economic climate.
- 2026 Outlook: The company anticipates no material revenue from its Early Access Program engagements in 2026, while expecting operating expenses to rise by 15-20% year-over-year, which may pressure profitability.
- Sufficient Funding: Based on its cash reserves as of December 31, 2025, Nautilus Biotechnology believes it has adequate resources to fund operations through 2027, demonstrating confidence and foresight in its financial management.
BETA Technologies Upgraded to Buy by Jefferies Amid Potential Catalysts
- Jefferies Upgrade: On February 11, 2026, Jefferies analyst Sheila Kahyaoglu upgraded BETA Technologies from Hold to Buy with a $30 price target, indicating that the shares are compelling at current levels following recent risk-off trading, suggesting potential for future gains.
- Amazon Investment Increase: As of December 31, 2025, Amazon acquired a $331.58 million position in BETA Technologies, making it one of its largest equity holdings, reflecting confidence in the electric aviation market and potentially providing financial support for BETA's future developments.
- Partnership Initiative: Surf Air Mobility announced a collaboration with the Hawaii Department of Transportation and BETA Technologies for the Electric Vertical Takeoff and Landing Integration Pilot Program, aiming to integrate airline operations with electric aircraft technology, which could enhance infrastructure development in Hawaii if selected.
- Electric Aviation Market Potential: BETA Technologies focuses on developing electric aircraft and propulsion systems, and as demand for sustainable aviation solutions grows, the company's technological innovations in the electric aviation sector are expected to drive significant future growth.
Nautilus (NAUT) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth
Biotech Stocks Momentum: Several small-cap biotech stocks, including Nautilus Biotechnology and PepGen, are experiencing renewed investor interest due to insider buying, strategic partnerships, and clinical trial advancements, leading to notable after-hours gains.
Nautilus Biotechnology Highlights: Nautilus saw a significant rise in stock price following insider purchases by its CEO and a partnership with the Allen Institute, alongside a reported narrower loss and strong cash position.
Lixte Biotechnology's Financial Strategy: Lixte announced a $2.6 million investment in Bitcoin and Ethereum to diversify its treasury, reflecting a strategic shift aimed at enhancing flexibility in the digital economy.
RenovoRx and VolitionRx Developments: RenovoRx received positive feedback for its pancreatic cancer trial and is expanding commercialization efforts, while VolitionRx entered a partnership to advance its diagnostic technology for Antiphospholipid Syndrome.
